The Food and Drug Administration (FDA) has approved Journavx™ (suzetrigine) for the treatment of moderate to severe acute pain in adults.

Yahoo Finance host Josh Lipton breaks down the day's top trending stocks and market stories in the Market Minute. AbbVie (ABBV) shares continue to pop in Friday trading after raising its revenue ...

The U.S. Food and Drug Administration (FDA) has approved Journavx, a new pain reliever without the risks of addiction or ...

It was given to people who had acute surgical pain from either abdominoplasty, also known as a tummy tuck, or bunion surgery.

Vertex Pharmaceuticals (VRTX) stock is rising following Food and Drug Administration (FDA) approval of Journavx, a non-opioid ...

The US Food and Drug Administration said it approved Vertex Pharmaceuticals' Journavx for short-term pain that often follows ...

Vertex Pharmaceuticals (VRTX) is up more than +4% after receiving FDA approval for its non-opioid analgesic Journavx to treat moderate-to-severe acute pain in adults. LPL Financial Holdings (LPLA) is ...

Vertex Pharmaceuticals could soon capture $10 billion in sales of non-opioid painkillers, an analyst said Friday as Vertex stock jumped.

The S&P 500 Index ($SPX) (SPY) today is up +0.67%, the Dow Jones Industrials Index ($DOWI) (DIA) is up +0.04%, and the Nasdaq ...

Introducing Journavx as a Safe Opioid Alternative for Pain Relief"** In a notable development, the FDA has granted approval for Journavx, positioning it as a viable alternative to opioids for pain ...

For those who may need relief from pain, Journavx symbolizes not only a new option but also a significant step forward in how we can tackle the challenges of pain management in the 21st century. The ...